1. What is Retatrutide?

Retatrutide is an investigational peptide that acts on three hormone receptors at once: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide) and glucagon. Because of this, it is often described as a "triple agonist" or "triple G" compound.

It was developed by Eli Lilly and has been studied in clinical trials for obesity, type 2 diabetes and related metabolic conditions.

2. How does it work?

GLP-1 and GIP are gut hormones involved in appetite and blood sugar regulation, while glucagon plays a role in energy expenditure and fat metabolism. By activating all three receptors, retatrutide is being researched for its combined effect on appetite, insulin response and energy use.

3. Research status

Retatrutide is still being evaluated in clinical research. This product is supplied as a sterile lyophilized powder for research purposes only and is not intended for human consumption.